evipedia.aidev
← Back

Serrapeptase for Health & Longevity

Evidence Review created on 08/14/2026 using AI4L / Grok 4.5

Also known as: Serratiopeptidase, Serratia peptidase, Serrapeptidase, Serralysin, Danzen, Dasen, Nicolase, Serodase

Motivation

Serrapeptase is a protein-digesting enzyme first taken from bacteria that live in silkworms. It is sold as an oral supplement and, in some countries, as a medicine. Interest among people who track inflammation, sinus mucus, and long-term blood-vessel health comes from its reputation for breaking down leftover protein at swollen or obstructed sites.

The enzyme was first used in East Asia as a short course after surgery or for chest and sinus mucus. It later entered Western supplement catalogs as a milder alternative to common anti-inflammatory drugs, and some clinics promoted it for clearing arterial plaque. Regulators in Japan and Singapore later dropped its medicine status after new trials failed to confirm benefit, while it remains widely sold as a supplement.

This review gathers clinical trials, safety reports, and laboratory work on serrapeptase. It examines what is known about swelling, mucus, and blood-vessel claims, and it sets those findings against bleeding risk, rare lung reactions, and the quality of the underlying studies.

Benefits - Risks - Protocol - Conclusion

High-level overviews that name serrapeptase and set out its claimed uses, mechanism, and evidence limits.

No dedicated serrapeptase content was found from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, or Lifespan.io.

Grokipedia

  • Serratiopeptidase

    Compact overview of discovery, chemistry, mixed clinical evidence, and commercial status, including the 1968 Japanese approval history.

Examine

  • Serrapeptase

    Independent evidence grades across sinus, surgical recovery, and related outcomes, with a direct assessment that many trials were poorly controlled.

ConsumerLab

A dedicated ConsumerLab CL Answer exists but is members-only; no freely retrievable full-text URL of that cited article was found.

Systematic Reviews

Published systematic reviews and meta-analyses that directly evaluate serrapeptase.

No systematic review of the principal risks (bleeding or drug-induced lung injury) was found on PubMed as of 14 August 2026. The 2016 Cochrane breast-engorgement review is superseded by the 2020 update and is not listed separately.

Mechanism of Action

Serrapeptase is a zinc-dependent metalloprotease (a protein-cutting enzyme that uses zinc at its active site; EC 3.4.24.40, the Enzyme Commission classification) secreted by Serratia marcescens, historically isolated from the gut of the silkworm Bombyx mori. It hydrolyzes nonterminal peptide bonds in fibrin (the mesh of a blood clot), mucus glycoproteins, and inflammatory exudate. Proposed anti-edema effects include breakdown of bradykinin (a peptide that promotes pain and vascular leak) and thinning of protein-rich fluid at injured sites, which may ease drainage.

A competing account holds that little intact enzyme survives digestion. Human absorption has not been quantified. Rat work detected active enzyme in plasma and lymph after high oral doses, with peaks between 30 minutes and 2 hours. Enteric coating (an acid-resistant shell that dissolves in the intestine) is used because gastric acid inactivates the protein. The enzyme is degraded by ordinary proteolysis, not by cytochrome P450 enzymes (CYP, the main liver drug-metabolizing system). A human half-life has not been established; one secondary report states the enzyme remained measurable for about 6 hours.

Selectivity is claimed for non-vital protein over living tissue, but that preference is not rigorously proven. Some narrative reviews describe affinity for cyclooxygenase (COX, the enzyme blocked by ibuprofen-class drugs); biochemical classification as a metalloprotease, not a COX-selective serine protease, makes that claim uncertain. In vitro, the enzyme can disrupt bacterial biofilms (the protein-rich slime that helps bacteria stick) by digesting matrix proteins.

Historical Context & Evolution

Serrapeptase entered Japanese medical practice in 1968 as Takeda’s Dasen/Danzen, labeled for postoperative swelling, sinusitis, breast engorgement, and mucus clearance in bronchitis, asthma, and tuberculosis. European and Indian clinicians later adopted the enzyme, often combined with nonsteroidal anti-inflammatory drugs (NSAIDs, common pain relievers such as diclofenac or aceclofenac). US supplement marketing from the late 1990s emphasized a “natural aspirin” story: inflammation control without gastric bleeding, plus anecdotal arterial-plaque claims associated with Hans Nieper’s clinic reports.

The original use was short-course anti-inflammatory and mucolytic (mucus-thinning) drug therapy, not longevity. Longevity interest grew from fibrinolytic and anti-biofilm marketing—claims that the enzyme might clear fibrin, scar, or arterial plaque—rather than from lifespan trials. Those plaque claims rest on anecdote; no controlled vascular-outcome study has tested them.

In 2011 Takeda, the originator company, voluntarily withdrew Dasen after post-marketing trials failed to show anti-inflammatory benefit over placebo. Singapore’s Health Sciences Authority then concluded there was no substantive evidence to retain medicinal-product status and phased out registered preparations, while allowing supplement use. The enzyme remains an over-the-counter or prescription product in parts of Asia and a dietary supplement in the United States and Canada. Withdrawal reflected failed confirmation of benefit, not a newly discovered toxicity.

Expected Benefits

Dedicated searches of PubMed, ClinicalTrials.gov, Examine, ConsumerLab, Drugs.com, and expert sources were performed for the full benefit profile before this section was written.

Low 🟩

Reduced soft-tissue swelling after surgery or injury ⚠️ Conflicted

A 174-person sinus-surgery study found less cheek swelling than placebo. A five-trial meta-analysis found no swelling edge versus corticosteroids; a 150-person third-molar trial and Takeda’s unpublished ankle work found none versus placebo (Bhagat 2013). A 2024 ankle-sprain study reduced edema more than paracetamol; the split tracks site, comparator, and publication.

Magnitude: Where positive, peak buccal swelling was about 2 mm less than placebo after antrotomy (sinus surgery that opens the maxillary sinus through the mouth); Takeda’s larger ankle trials report no measurable difference.

Improved mouth opening after third-molar surgery

A meta-analysis of five trials (n = 474) reported greater mouth opening than corticosteroids. A later 133-person trial reported a significant day-4 mouth-opening difference versus placebo-plus-paracetamol. An earlier crossover found no trismus (restricted mouth opening) difference. Pooled study quality was low.

Magnitude: Pooled mean difference 4.42 mm greater opening versus corticosteroids (95% CI 3.84 to 5.00; CI = confidence interval, the plausible range for the true difference).

Reduced ear, nose, and throat inflammatory symptoms

One multicenter double-blind trial in 193 people with acute or chronic ear, nose, or throat disorders reported faster pain, secretion, and blockage relief versus placebo over 7–8 days. Completer analysis (n = 140; results counted only in people who finished) and older methods limit certainty.

Magnitude: Pain and secretion scores each improved by about 1 point more than placebo on a 4-point clinician scale.

Thinner airway mucus ⚠️ Conflicted

An open 29-person trial in chronic bronchitis or bronchiectasis (permanently widened airways) reported lower sputum weight and viscosity after 30 mg/day for 4 weeks. Takeda’s unpublished 311-person placebo trial (Bhagat et al., 2013) found no expectoration difference, tracking open-label versus blinded design.

Magnitude: In the open trial, mucociliary transportability rose from 13.3 to 24.4; the larger manufacturer trial reports no benefit on the primary sputum-clearance endpoint.

Reduced postpartum breast engorgement

A 70-person double-blind trial of Danzen 30 mg/day for 3 days reported more moderate-to-marked improvement than placebo. Cochrane rates the finding as low-certainty.

Magnitude: Risk of remaining engorged versus placebo, risk ratio 0.36 (95% CI 0.14 to 0.88; risk ratio = how many times as often the outcome occurs).

Reduced postoperative pain ⚠️ Conflicted

A third-molar crossover found lower pain when 5 mg was added to paracetamol. A 150-person comparison found no analgesic effect versus placebo, and dexamethasone outperformed 10 mg serrapeptase. The split tracks dose (5 vs 10 mg) and comparator.

Magnitude: Not quantified in available studies. Positive trials report directional pain-score reductions without a pooled effect size; negative trials report no difference from placebo.

Speculative 🟨

Arterial plaque or clot clearance

Clinic anecdotes associated with Hans Nieper describe plaque reduction. No controlled human angiography or event trial exists; Bhagat et al., 2013 treat the claim as unsupported.

Amyloid-beta breakdown

In vitro, serrapeptase can fragment Aβ1–42 (a protein that aggregates in Alzheimer plaques) and lower its cell toxicity (Metkar et al., 2024). No human cognitive or biomarker trial exists.

Bacterial biofilm disruption

Laboratory work shows digestion of Escherichia coli curli fibers and other matrix proteins at nanogram concentrations (Katsipis et al., 2025). No human infection-outcome trial tests oral supplement doses.

Carpal tunnel symptom relief

An uncontrolled 20-person series reported clinical and nerve-test improvement in 65% after 10 mg twice daily plus a short nimesulide course, with four recurrences. There was no placebo arm.

Benefit-Modifying Factors

  • Genetic polymorphisms: No CYP or transporter variants are known to change serrapeptase response. The enzyme is not a CYP substrate, so common pharmacogenetic panels are not used to set dose.

  • Baseline inflammatory load: Trials enroll people with active surgical trauma, sinus inflammation, or sputum production. People without that protein-rich exudate have no demonstrated benefit signal.

  • Baseline biomarkers: No pre-start C-reactive protein (CRP, a blood inflammation marker), fibrinogen, or sputum-weight cut-off is used to pick responders. Enrollment is clinical, so those labs alone do not mark a benefit.

  • Sex: One carpal-tunnel series was two-thirds female, matching disease mix, not a proven sex-response difference. Breast-engorgement data apply only to lactating women.

  • Pre-existing conditions: Chronic airway disease was the setting for sputum-property changes. Active abscess, a bleeding tendency, or eosinophilic lung disease changes the risk side more than the benefit side.

  • Age: Pivotal dental trials enroll adults around 20–40 years. Older adults appear mainly in safety case reports, not in benefit trials, so efficacy after midlife is untested.

Potential Risks & Side Effects

A dedicated search of PubMed, Drugs.com, Health Canada monograph material summarized by Drugs.com, Japanese case series, and trial adverse-event text was performed before this section was written.

Low 🟥

Gastrointestinal discomfort

Short trials totaling more than 1,400 participants report an adverse-event rate similar to placebo (Bhagat et al., 2013). Gastric pain is named in the Mazzone trial. Those trials lasted 1–4 weeks and do not describe long-term gut effects.

Magnitude: Incidence similar to placebo in short trials; no pooled event rate is published.

Hypersensitivity and ordinary skin reactions

Rash and other hypersensitivity reactions appear in monographs and in the Mazzone trial. They are the milder end of a spectrum that, in rare case reports, includes blistering disease.

Magnitude: Not quantified in available studies. Trials were too small and short to estimate a reliable incidence.

Drug-induced eosinophilic pneumonia

At least four Japanese case reports describe fever, cough, hypoxia (low blood oxygen), and eosinophilic pneumonia (allergic-type lung inflammation) during use, including immune-cell confirmation and a Nicolase case after prior idiopathic pneumonia. Short efficacy trials did not capture this event.

Magnitude: Not quantified in available studies. Only isolated case reports exist; trial datasets were too small to measure a rare pulmonary rate.

Speculative 🟨

Increased bleeding

Fibrinolytic activity is the theoretical basis for a bleeding interaction with anticoagulants. Bhagat et al., 2013 note this caution. Controlled trials have not measured excess bleeding.

Severe blistering skin reactions

A diclofenac–serrapeptase combination was followed by Stevens-Johnson syndrome (severe blistering of skin and mucosa); diclofenac alone can cause this. A letter describes blistering dermatosis attributed to the enzyme.

Spread of a walled-off infection

Case authors have proposed that digesting fibrin around an abscess could allow infection to track deeper. The supporting pharmacology is disputed, and the evidence is anecdotal.

Risk-Modifying Factors

  • Genetic polymorphisms: No HLA (immune-identification genes) or metabolic variant is established for serrapeptase lung or skin injury. Standard pharmacogenetic panels do not currently modify this risk.

  • Baseline biomarkers: Unexplained eosinophilia (a high allergy-type white-cell count) or a prior drug-induced pneumonia raises concern, because re-exposure has reproduced lung injury in case reports.

  • Sex: Published pneumonia and blistering cases include both men and women. No consistent sex difference in adverse-event rates is documented.

  • Pre-existing conditions: Bleeding disorders, concurrent anticoagulants, active abscess, and known enzyme allergy are the main clinical modifiers. Pregnancy and lactation lack safety data.

  • Age: Serious lung-injury reports cluster in older adults. Short dental trials in young adults do not define risk after age 65.

Key Interactions & Contraindications

  • Anticoagulants and antiplatelet drugs (warfarin, apixaban, clopidogrel, aspirin): Caution. Theoretical increase in bleeding because of fibrinolytic activity. Monitoring of bruising, stool color, and clotting tests is the usual mitigation.

  • NSAIDs (ibuprofen, diclofenac, aceclofenac): Caution, especially in Indian combination tablets. Additive bleeding and, in one report, severe skin reaction on a diclofenac combination. Separation is not established; combination products are common.

  • Other proteolytic supplements (nattokinase, lumbrokinase, bromelain, high-dose systemic protease blends): Caution. Additive fibrin and clot effects are plausible. Timing on an empty stomach adds concurrent exposure rather than separating it.

  • Antibiotics (cefotiam, sulbenicillin, ofloxacin in older work): Monitor. Small clinical and animal studies report greater tissue antibiotic levels and biofilm disruption, which can help or, in theory, unmask a walled infection.

  • Food protein at the same time: Caution. A meal presents competing substrate and is expected to keep the enzyme in the gut as a digestive aid rather than a systemic agent. Empty-stomach timing (30 minutes before or 2 hours after food) is the usual mitigation.

Populations who should avoid Serrapeptase:

  • Known hypersensitivity to serrapeptase or Serratia enzymes
  • Active or recent significant bleeding, or planned surgery within about 2 weeks
  • Current anticoagulant or dual-antiplatelet therapy unless bleeding risk is already being managed
  • Pregnancy or lactation (no adequate safety data)
  • Prior drug-induced eosinophilic pneumonia or unexplained eosinophilia
  • Active untreated abscess or deep infection
  • Children (almost all trials are in adults)

Risk Mitigation Strategies

  • Enteric coating against gastric pain: An enteric-coated dose 30 minutes before or 2 hours after food is used so the protein is not released in the stomach, the site of gastric pain in short trials.

  • Short initial course: Historical drug labeling used 1–2 weeks for swelling and up to 4 weeks for mucus. Shorter exposure limits cumulative time at risk for rare lung injury.

  • Hold before procedures: Stopping several days before elective surgery or dental extraction is used to reduce theoretical bleeding, given the unknown human half-life.

  • Watch for lung and skin signals: New cough, breathlessness, fever, rash, or mucosal erosions are the published trigger for stopping, to limit further lung or blistering injury.

  • Avoid combining clot-active agents: Combining with warfarin, direct oral anticoagulants, high-dose fish oil, or other systemic proteases is treated as a bleeding-risk combination.

  • Abscess caution: Case authors treat an undrained collection as a reason to withhold the enzyme, because fibrin digestion is the proposed pathway for infection spread.

Therapeutic Protocol

  • Historical drug schedule: Takeda’s labeled anti-inflammatory course was 10 mg three times daily after meals for 1–2 weeks. Mucolytic courses in trials used the same 30 mg/day dose for 2–4 weeks.

  • Supplement practice: Commercial protocols use 10–60 mg/day (about 20,000–120,000 serrapeptase units) on an empty stomach, often split every 8 hours. Health Canada caps licensed products at 60 mg/day.

  • Integrative combinations: Some clinics pair serrapeptase with nattokinase or bromelain as a “systemic enzyme” combination. That combination is a competing approach, not a default, and adds bleeding uncertainty.

  • Time of day: Split morning, afternoon, and evening doses match the short detection window (measurable for hours, not a full day). Night-only dosing is a consumer pattern, not a trial standard.

  • Half-life and splitting: Human half-life is not established. Rat peaks occur at 30 minutes to 2 hours; secondary sources say the enzyme may remain detectable about 6 hours, which is why split doses are used.

  • Genetic dose modifiers: No APOE4 (fat-transport gene), MTHFR (folate gene), COMT (catecholamine-clearing gene), or CYP variant is known to change serrapeptase dose.

  • Sex: No sex-specific dose is supported. Breast-engorgement data do not generalize to a different maintenance dose in women.

  • Age: Older adults have no separate efficacy dose and are over-represented in lung-injury reports, so conservative duration is the usual adjustment.

  • Baseline biomarkers: There is no target blood level. People without active exudative inflammation have no evidence-based dose to “optimize.”

  • Pre-existing disease: Bleeding risk, pregnancy, and prior drug pneumonia change whether the protocol is used at all, not the milligram step.

Discontinuation & Cycling

  • Duration intent: Licensed drug use was short-term (days to a few weeks). Daily longevity use is a supplement-market practice, not a studied lifelong indication.

  • Withdrawal: No withdrawal syndrome is described. Stopping does not produce a rebound physiology in published reports.

  • Taper: Tapering is not required. The enzyme is not a receptor agonist with downregulation data.

  • Cycling: No trial tests on/off cycles for preserved efficacy. Cycling is sometimes used by supplement users to limit continuous proteolytic exposure; that practice is empirical.

  • Restart after illness: Case reports of pneumonia after a later enzyme course argue against restarting after a suspected drug-lung event.

Sourcing and Quality

  • Enteric coating: Health Canada accepts only enteric-coated oral forms. Uncoated powder is expected to lose activity in stomach acid.

  • Unit labeling: About 2,000–2,600 Japanese Pharmacopoeia units equal 1 mg; 10 mg is roughly 20,000 serrapeptase units. Labels that state only “mg” without activity units are harder to compare.

  • Third-party testing: Independent identity, activity, and contaminant assays matter because fermentation products vary. USP (United States Pharmacopeia) or ISO (International Organization for Standardization)-accredited certificates are the usual quality signal.

  • Brands and pharmacies: Life Extension, Doctor’s Best, and Arthur Andrew market standalone or blend products in the US. Indian pharmacies sell Danzen-type and NSAID-combination tablets that are not interchangeable with a US supplement.

  • Combination tablets: Aceclofenac–paracetamol–serratiopeptidase products (for example Zerodol SP) add NSAID risk and are a different intervention from the enzyme alone.

Practical Considerations

  • Time to effect: Swelling and pain trials measure days 1–7. Mucus-property changes were assessed at 2–4 weeks. Plaque or amyloid claims have no human time course.

  • Common pitfalls: Taking the enzyme with meals; using a non-enteric product; expecting artery-plaque clearance; combining several “systemic enzymes”; and treating an undrained abscess as an enzyme problem.

  • Regulatory status: Not FDA-approved as a drug in the United States; sold as a dietary supplement. Takeda withdrew the Japanese drug in 2011. Singapore phased out medicinal licenses. Canada licenses enteric-coated natural health products.

  • Cost and access: Typical US commercial products cost on the order of 10–30 dollars per month at 10–30 mg/day. Access is easy; quality is the constraint, not price.

Interaction with Foundational Habits

  • Sleep: None. Night-time empty-stomach dosing is used so that a meal does not compete, not because the enzyme is sedating or alerting. New nocturnal cough or breathlessness is a safety signal, not a sleep benefit.

  • Nutrition: Direct, substrate-level. Protein-containing meals are expected to occupy the enzyme in the gut. Protocols therefore separate the dose from food by 30 minutes before or 2 hours after eating; fasting windows make that timing easier.

  • Exercise: Indirect. Reduced post-injury swelling is the claimed athletic use (ankle-sprain data are conflicted). Contact sport plus a fibrinolytic enzyme theoretically raises bruise risk; no sport-performance trial exists.

  • Stress management: Indirect at most. Any change in perceived swelling or sinus pressure could alter comfort, but no cortisol or autonomic study isolates serrapeptase from that context.

Monitoring Protocol & Defining Success

Baseline assessment, when the enzyme is used, centers on whether an exudative problem is actually present and whether bleeding or lung risk is already elevated. A pre-start complete blood count with differential documents the eosinophil (allergy-associated white cell) fraction. High-sensitivity C-reactive protein (hs-CRP, a blood marker of systemic inflammation) and fibrinogen give a personal inflammation and clot-protein baseline. Clotting tests (prothrombin time / international normalized ratio, PT/INR) matter if anticoagulants or a bleeding history are in play. There is no serrapeptase blood level to target.

Ongoing labs, if used, are checked at about 2–4 weeks, then every 3–6 months during continued use, and promptly if cough, rash, or bruising appears. Success in the trial literature is less swelling, better mouth opening, or thinner sputum over days to weeks—not a change in lifespan, artery imaging, or cognition.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
hs-CRP <0.7 mg/L Tracks whether systemic inflammation is present to modify Conventional often cites <3.0 mg/L; fast 8–12 hours
Eosinophils <3% or <300 cells/µL Screens for evolving drug-lung or allergic signal Conventional upper limit often 5% or 500 cells/µL
Fibrinogen 200–300 mg/dL Baseline clot protein if fibrinolytic use is the rationale Conventional 200–400 mg/dL; pair with hs-CRP
PT/INR 0.9–1.1 if not anticoagulated Detects a bleeding-risk shift on combined agents Draw if on warfarin or if bruising appears
Hemoglobin No enzyme-specific target; track change from own baseline Flags occult blood loss Fasting not required

Qualitative markers:

  • Sinus pressure, nasal discharge, and sputum stickiness
  • Surgical-site swelling, bruise size, and mouth opening
  • New cough, breathlessness, fever, or rash
  • Unusual bruising, nosebleeds, or dark stool
  • Energy and local pain scores versus the person’s own week-zero notes

Emerging Research

  • Fresh third-molar trial: NCT07543146 randomized 110 adults to postoperative serratiopeptidase versus standard care for swelling and trismus (completed 2025; no results posted). A positive or null read would move the conflicted swelling literature.

  • Enzyme versus escin: NCT07304882 is a completed 24-person split-mouth phase 3 comparison of 10 mg serratiopeptidase versus escin after wisdom-tooth surgery. Small n limits any longevity inference.

  • Triple-enzyme supplement: NCT07269171 is not yet recruiting (n = 15) and tests a trypsin–chymotrypsin–serratia peptidase food supplement after extraction. A combo design cannot isolate serrapeptase.

  • Negative fibrosis signal: Bruno & Saccoccio 2026 found no elastography (ultrasound stiffness) benefit of 60,000 IU (international units)/day for 4 weeks after liposuction for lipedema (painful fat-distribution disorder) versus usual care (PMID 41642311).

  • Biofilm and amyloid lab work: Katsipis 2025 reports E. coli biofilm clearance in vitro (PMID 40871379); Metkar 2024 reports Aβ1–42 digestion in vitro (PMID 35694981). Neither is a human outcome study.

  • Still missing: A modern, independently run absorption study in humans, and any trial with artery imaging, cognition, or lifespan as the endpoint, would be required to move the longevity claims off a speculative footing.

Conclusion

Serrapeptase is a protein-digesting enzyme first used as a short-course swelling and mucus drug, later sold as a daily supplement for inflammation and, more speculatively, for arterial plaque clearance. The strongest published signals are small, short trials in dental surgery, ear-nose-throat irritation, and postpartum breast fullness. Larger manufacturer trials that were never fully published found no advantage over placebo for ankle swelling or for difficulty bringing up sputum. Independent reviewers have judged the overall evidence insufficient to support routine pain-relief or heart-health use.

For a health-optimizing adult, the practical picture is a low-cost enzyme with a plausible local anti-swelling mechanism, unproven absorption in humans, and no data on lifespan, artery plaque, or brain-protein clearance in people. Short trials report a side-effect rate similar to placebo. Rare lung inflammation, skin blistering, and a theoretical bleeding interaction with anticoagulants appear in case reports. Several authors of favorable reviews (Jadhav et al., affiliated with Advanced Enzymes Technologies and Specialty Enzymes), and the original brand manufacturer Takeda, had a commercial stake in the product; that stake is part of how the evidence base was produced.

The enzyme is not framed here as settled help or settled harm. It is a protein whose human absorption is unproven, whose short-term surgical and mucus claims remain mixed, whose longevity claims are untested, and whose serious harms are uncommon but documented.

Top - Benefits - Risks - Protocol